Eprosartan mesylate, an angiotensin II receptor antagonist

被引:1
|
作者
Qian, Jing-Jing [2 ]
Hu, Xiu-Rong [1 ]
Gu, Jianming [1 ]
Wu, Su-Xiang [2 ]
机构
[1] Zhejiang Univ, Ctr Anal & Measurement, Hangzhou 310028, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China
关键词
DOUBLE-BLIND; HYPERTENSION; MULTICENTER; BEHAVIOR;
D O I
10.1107/S1600536811006659
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carboxybenzyl)-5-[(E)-2-carboxy-3-(thiophen-2-yl)prop-1-enyl]-1H-imidazol-3-ium methanesulfonate}, C23H25N2O4S+center dot CH3O3S-, one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in the treatment of congestive heart failure, renal failure and glaucoma. In the eprosartan residue, which appears in this crystal in the cationic imidazolium form, the benzene ring plane is almost orthogonal to that of the imidazole ring, making a dihedral angle of 87.89 (2)degrees. The thiophene ring forms dihedral angles of 66.54 (2) and 67.12 (2)degrees with the benzene and imidazole rings, respectively. The imidazolium NH group and the H atom of the aromatic carboxyl group participate in hydrogen bonds with the the O atoms of the anion, thus forming centrosymmetric aggregates made up of two cations and two anions each. The second carboxyl group further links the above-mentioned aggregates through a conventional centrosymmetric hydrogen-bonding motif into infinite chains along [011].
引用
收藏
页码:O770 / U1389
页数:13
相关论文
共 50 条
  • [41] Management of hypertension: the advent of a new angiotensin II receptor antagonist
    Hedner, T
    JOURNAL OF HYPERTENSION, 1999, 17 : S21 - S25
  • [42] Hepatotoxicity due to angiotensin II receptor antagonist/hydrochlorothiazide combination
    Salouage, I
    Kastalli, S
    El Aïdli, S
    Zaïem, A
    Daghfous, R
    Lakhal, M
    Loueslati, MH
    Belkahia, C
    DRUG SAFETY, 2005, 28 (10) : 952 - 953
  • [43] Synthesis of a novel angiotensin II receptor antagonist olmesartan medoxomil
    Yu, Xin-Hong
    Tang, Jian
    Wen, Xin-Min
    Mao, Qing-Hua
    Shen, Yong-Jia
    Huadong Ligong Daxue Xuebao /Journal of East China University of Science and Technology, 2005, 31 (02): : 189 - 192
  • [44] Antiproteinuric effect of an angiotensin II receptor antagonist in membranous nephropathy
    Miyauchi, N
    Nakamura, Y
    NEPHRON, 2001, 88 (02): : 183 - 184
  • [45] Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension
    Hjermitslev, Marie
    Grimm, Daniela G.
    Wehland, Markus
    Simonsen, Ulf
    Krueger, Marcus
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (04) : 225 - 233
  • [46] Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan
    Meredith, PA
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (2A): : 7K - 12K
  • [47] Use of an angiotensin II receptor antagonist in polydipsia-hyponatremia
    Verghese, C
    Nair, C
    Abraham, G
    Stanilla, JK
    Josiassen, RC
    BIOLOGICAL PSYCHIATRY, 1997, 41 : 407 - 407
  • [48] DISCOVERY OF LOSARTAN, THE FIRST ANGIOTENSIN-II RECEPTOR ANTAGONIST
    TIMMERMANS, PBMWM
    DUNCIA, JV
    CARINI, DJ
    CHIU, AT
    WONG, PC
    WEXLER, RR
    SMITH, RD
    JOURNAL OF HUMAN HYPERTENSION, 1995, 9 : S3 - S18
  • [49] Clinical overview of irbesartan - A new angiotensin II receptor antagonist
    Pouleur, HG
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) : 318S - 324S
  • [50] Efficient synthesis of valsartan, a nonpeptide angiotensin II receptor antagonist
    Zhang, C
    Zheng, GJ
    Fang, LJ
    Li, YL
    SYNLETT, 2006, (03) : 475 - 477